REVOLUTION MEDICINES INC. - COMMON STOCK

56,89

25-ноября-24 10:09:32

15 мин. задержка

Акции

+0,13

+0,24%

Сегодняшний диапазон

56,82 - 57,97

ISIN

N/A

Источник

NASDAQ

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06 ноя 2024 16:02:32 Источник Nasdaq GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences

05 ноя 2024 09:00:30 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30 окт 2024 16:05:23 Источник Nasdaq GlobeNewswire
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

25 окт 2024 04:15:00 Источник Nasdaq GlobeNewswire
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 окт 2024 06:00:49 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 окт 2024 16:05:39 Источник Nasdaq GlobeNewswire
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 окт 2024 09:00:01 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 авг 2024 16:05:41 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 июл 2024 16:05:11 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 июл 2024 12:00:53 Источник Nasdaq GlobeNewswire
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 июн 2024 16:05:28 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

08 май 2024 16:02:54 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

01 май 2024 16:05:56 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 апр 2024 15:34:07 Источник Nasdaq GlobeNewswire
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 апр 2024 11:36:55 Источник Nasdaq GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences

04 апр 2024 16:05:04 Источник Nasdaq GlobeNewswire
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 мар 2024 16:05:40 Источник Nasdaq GlobeNewswire
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 фев 2024 16:05:50 Источник Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 фев 2024 16:05:47 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.